[Question] non-peptide — what am I missing here
Trying to get a straight answer on this: non-peptide — what am I missing here.
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
Why "oral" is doing two completely different jobs in the sentences people write here.
Oral semaglutide is a peptide co-formulated with an absorption enhancer, which is why it comes with food and water timing requirements. This compound is a non-peptide small molecule that activates the same receptor, formulated as an ordinary tablet.
The practical consequences differ enormously: no timing constraints, a conventional manufacturing route, different stability behaviour, and a different analytical problem for anybody trying to verify identity or purity. Whenever a thread here compares the two, check which sense of "oral" each half is using.
Went looking for independent testing on this and found essentially nothing, which was clarifying.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
[deleted]
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
oral semaglutide is a peptide with an absorption enhancer, this is not that
Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve.
Adding the standing caveat — unapproved, and research material is not for human use.
Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
oral and non-peptide is the whole engineering story
nothing containing this is approved anywhere yet
Which programme and which readout are you quoting?
Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.
Retitled to name the programme. It is what makes these threads findable in a year.
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.
Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.
Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.
Is that from the publication or the press release?
Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.
Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.
a non-peptide agonist does not degrade the way a peptide does
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Are you comparing doses across a small molecule and a peptide?
nothing containing this is approved anywhere and research material is not for human use
Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
This. The absence of food and water timing restrictions is the practical difference people will actually notice.
- 1Retitled to name the programme. It is what makes these threads findable in a…15 comments in this branch · started by u/phase_two_pete
- 2Daily dosing gives a very different exposure profile from a weekly…11 comments in this branch · started by u/marit_sandvik